Immunitas Therapeutics names new CEO
17 November 2021 -

Immunitas Therapeutics, a US-based single cell genomics-based therapeutics company, announced on Tuesday that it has named Amanda Wagner, MBA, as its new chief executive officer.

Wagner is a founding member of Immunitas and has over 15 years of experience in drug discovery, drug development, and medical technology, and has led teams from discovery through clinical development of novel immune-modulating therapies. She has held the position of vice president of corporate development at Q32 Bio. She has also served at Concert Pharmaceuticals and was an early member of the team at UpToDate Inc. She is also the director of the National Alopecia Areata Foundation.

Wagner said, 'I am honoured to assume the role of CEO at Immunitas, and excited for the future of the company. I am passionate about the Immunitas mission to discover, develop, and deliver novel immuno-oncology therapeutics to patients with cancer, and look forward to further growing our team and pipeline. As a company we are strongly positioned to have a meaningful impact on patients' lives. Echoing the sentiments of everyone at Immunitas, I thank Jeff for all he has done over the past two years to set us on a path for continued growth.'